Autopsy report · NCT05953545

Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis

“Study closure based on decision of the PI”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Sponsor type

US National Institutes of Health

Conditions

Chronic Hepatitis Delta

Interventions

Peginterferon Lambda

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma
  “Study closed by PI due to lower than expected accrual.” (73% match in meaning)
• Developing and Validating Fertilit-e
  “PI decision - competing study” (68% match in meaning)
• Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water
  “PI retired, study closed” (66% match in meaning)
• Postoperative Chemoradiation or Chemotherapy After Preoperative Chemotherapy for Gastric Cancers
  “The PI has decided to close the study due to the outdated study design.” (64% match in meaning)
• Comparison of Quadratus Lumborum Block Types
  “PI left the institution. Decision made to close the study.” (63% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.